Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13226857 | 0.90 | MEN1 (0.39) | EPHX2MEN1KMT2ANAMPTTSHR | |
| SCHEMBL17915501 | 0.86 | MEN1 (0.44) | EPHX2MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL10315825 | 0.85 | TSHR (0.38) | EPHX2MEN1KMT2ATSHRRECQL | |
| SCHEMBL16303480 | 0.85 | MEN1 (0.39) | EPHX2MEN1KMT2ATSHRRECQL | |
| SCHEMBL16303451 | 0.84 | MEN1 (0.41) | EPHX2MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL17563108 | 0.83 | EPHX2 (0.33) | EPHX2SMN1; SMN2ACHE | |
| SCHEMBL16560388 | 0.83 | MEN1 (0.54) | EPHX2MEN1KMT2ATSHRRECQL | |
| SCHEMBL24982522 | 0.83 | MEN1 (0.42) | EPHX2MEN1KMT2ATSHRCASP2 | |
| SCHEMBL16303444 | 0.82 | TSHR (0.44) | MEN1KMT2ATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL22214463 | 0.82 | MEN1 (0.44) | EPHX2MEN1KMT2ATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20170008941-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9481706-B2 | Purification of non-glycosylated polypeptides | HOFFMANN-LA ROCHE INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-8889837-B2 | Purification of pegylated polypeptides | HOFFMAN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140220633-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8795533-B2 | Chromatographic methods | HOFFMANN-LA ROCHE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140163207-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | HOFFMANN-LA ROCHE INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130190478-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | HOFFMANN-LA ROCHE INC. | 2013-07-25 | — | — | US | disclosed |
| US-20120197007-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-8138317-B2 | Purification of pegylated polypeptides | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7846896-B2 | PEG conjugates of NK4 | HOFFMAN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846336-B2 | regeneration of a cation exchange chromatography column for purification of polypeptides | HOFFMANN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090118476-A1 | Purification of pegylated polypeptides | HOFFMANN-LA ROCHE INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7459429-B2 | Method of treating disturbances of iron distribution in inflammatory intestinal diseases | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459435-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459436-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | BRANDT MICHAEL | 2008-04-10 | — | — | US | disclosed |
| US-7202208-B2 | Erythropoietin composition | HOFFMAN-LA ROCHE INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7169754-B2 | Erythropoietin composition | HOFFMANN-LA ROCHE INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220633-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | YIPF5, HASPIN, HM13 | EPHX2 3321/4885MEN1 3424/4885KMT2A 4305/4885 |
| US-20120197007-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | EPOR, TFRC, RPS27A | EPHX2 632/4885MEN1 3570/4885KMT2A 4293/4885 |
| US-20140163207-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | EPOR, TFRC, RPS27A | EPHX2 632/4885MEN1 3570/4885KMT2A 4293/4885 |
| US-20170008941-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | EPOR, TFRC, RPS27A | EPHX2 632/4885MEN1 3570/4885KMT2A 4293/4885 |
| US-20130190478-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | YIPF5, HASPIN, HM13 | EPHX2 3501/4885MEN1 3580/4885KMT2A 4348/4885 |
| US-20090118476-A1 | Purification of pegylated polypeptides | EPOR, HAMP, EGFR | EPHX2 212/4885MEN1 1273/4885KMT2A 3787/4885 |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | PBK, IL4, CD47 | EPHX2 2735/4885MEN1 2418/4885KMT2A 305/4885 |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | IAPP, HDGF, HGF | EPHX2 2862/4885MEN1 2210/4885KMT2A 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.